Article and Video CATEGORIES

Cancer Journey

Search By

Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)

 

ASCO Update on Pre-Operative Chemotherapy
Author
Howard (Jack) West, MD

Post-operative, also known as adjuvant chemotherapy, is the established method for delivering systemic therapy to improve long-term outcomes beyond what surgery alone can deliver. An alternative approach, though, is to give treatment prior to surgery. This gives the potential advantage of treating potential micrometastatic disease at the earliest opportunity, identifying the response to treatment given rather than treating "blind" with no disease to follow, and potentially delivering treatment more reliably because more patients will receive treatment as planned than in the post-operative setting, where many patients may drop out of consideration for chemo as they contend with recovering from surgery and potentially having complications.

Still, the higher profile pre-operative chemotherapy studies haven't been positive, or at least not positive enough. But it's worth reviewing what's being considered a negative study.

First, there was the SWOG 9900 trial, designed with a plan to enroll 600 patients to detect the differences they hoped to, but closing after only 354 were enrolled, in the face of a series of positive post-operative trials making it very difficult to continue to enroll patients on a trial of pre-op chemo vs. up front surgery, with no plan for adjuvant chemotherapy. This trial, for patients with stage IB - IIIA NSCLC (without N2 nodal disease, a higher risk group), gave 3 cycles of pre-operative carboplatin/Taxol (paclitaxel) and was reported as showing a non-significant trend toward more favorable survival in the chemotherapy recipients. Results are illustrated on the curves for progression-free and overall survival shown below:

swog-9900-pfs-curves swog-9900-os-curves

(click on images to enlarge)

Though these differences were not quite statistically significant, they both reflected an approximately 20% improvement with chemotherapy compared with surgery alone. Though some have speculated that these results may have been more favorable if a cisplatin-based regimen were used, the magnitude of relative improvement here with carbo/taxol seems very comparable to the results we've seen in positive adjuvant trials with cisplatin-based regimens, but the trial was definitely underpowered, closing with just under 60% of their intended patient enrollment completed.

This year at ASCO, we saw the long-term results of a French trial that used an older and arguably obsolete chemo regimen of mitomycin C, ifosfamide, and cisplatin (termed MIC or MIP, for cisplatin, or platinum, respectively) before surgery, compared with surgery alone. It actually had a fairly complex design with a few variants, shown below:

ifct-neoadjuvant-chemotherapy-trial-design

This study had actually been published in preliminary form all the way back in 2002, but the updated results with median follow-up beyond 13 years was presented by Dr. Virginie Westeel. This study did enroll higher risk patients with stage IIIA N2 NSCLC, who in North America would be excluded from trials that included surgery alone because of the unacceptably high risk of recurrence without chemotherapy before or after surgery. Importantly, not only were these patients enrolled on this study, but they were disproportionately assigned to the chemotherapy arm (42% vs. 28%, a nearly significant difference, at p = 0.065). This difference would be presumed to disfavor patients assigned to chemotherapy compared to the group assigned to surgery, with an arguably better prognosis.

What the results demonstrated was a non-significant trend toward more favorable survival in the recipients of pre-operative chemotherapy, with an 8-9% absolute difference that is maintained beyond 5 years and even out to 10 years:

ifct-long-term-os-curves-westeel-asco-2010

The differences in disease-free survival are of a similar magnitude, just slightly greater, but enough to actually now be statistically significant:

ifct-long-term-pfs-curves-westeel-asco-2010

So why would there be a difference between disease-free survival and overall survival so far out? The two reasons I can think of for that small difference would be death from competing medical problems over a long period of time, or death potentially as a complication or long-term consequence of chemotherapy.

Dr. Westeel and her colleagues also did a multivariate analysis in which the role of chemotherapy was separated from the differences in T stage, N stage, age, and other factors (remember that the chemotherapy arm had been assigned a higher risk population). Isolating that variable of chemotherapy revealed a statistically significant difference of an approximately 40% improvement.

In the commentary at ASCO, the new data from the French study were shown along with the SWOG 9900 trial, highlighting that the improvement in survival, in absolute terms, is very comparable to the benefits of chemotherapy in the post-operative setting. I believe this is quite true, but that both of these trials were underpowered to show a statistically significant benefit compared to the larger trials of adjuvant therapy.

But the best test of one strategy against another would be a trial in which patients in the same trial are randomized to either pre-operative or post-operative chemotherapy. That's what we'll turn to next.

Next Previous link

Previous PostNext Post

Related Content

Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Yang, Das, and Dagogo-Jack discuss commonly used terms in treatment options for lung cancer, how oncologists determine the stage of lung cancer, and what that means for treatment, the importance of driver mutation in NSCLC treatment, the vast number of NSCLC trials, among other topics which involve lung cancer treatments. To watch the complete playlist click here.
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Jeff Yang, discusses different surgical procedures used to treat early-stage lung cancer and different approaches to removing cancerous tissue from the lung. 
Image
Lung Cancer OncTalk 2023
Video
At our live event, Lung Cancer OncTalk 2023, Dr. Millie Das, discusses different Studies and Trials for NSCLC. Dr. Das specializes in the treatment of thoracic malignancies. She sees and treats patients both at the Stanford Cancer Center and at the Palo Alto VA Hospital. She is the Chief of Oncology at the Palo Alto VA and is an active member of the VA National Lung Cancer Working Group and Lung Cancer Precision Oncology Program. Learn more about Dr. Das here.

Forum Discussions

Hi Amber, Welcome to Grace.  I'm so sorry you're going through this scare.  It could be a recurrence.  It also is as likely to be the contrast creating a better view. ...

Hi Blaze,

 

As much as I hate to say it, Welcome back Blaze.  It sounds like you're otherwise feeling good and enjoying life which is a wonderful place to be. ...

Waiting for my appointment with oncologist this morning. Thank you for the response. It helps. <3

It sounds like you’re thinking of this in a very appropriate way. Specifically, it sounds like the growth of the nodule is rather modest, though keep in mind that the change...

Hi and welcome to GRACE.  I'm sorry your mom is having this difficulty.  An indwelling catheter is used when the pleura space continually fills and the catheter is always there to...

Recent Comments

JOIN THE CONVERSATION
Hi Amber, Welcome to Grace. …
By JanineT GRACE … on
Could you
By Maeve785 on
It sounds like you’re…
By Dr West on
Thank you Janine
By blaze100 on